Phage (PTXX): Antibiotics to fight super-resistant bugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Phage (PTXX): Antibiotics to fight super-resistant bugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bhag Karamchandani who wrote ()	2/5/2000 10:42:00 AM
From: PSC	Read Replies (1) of 23

Big, front-page article about the promise of phage-based antibiotic therapy in the era of antiobiotic drug resistance dated 6 Feb 2000. From having worked with phage in molecular biology, and knowing how serious the advent of drug resistance is felt to be working as a physician, this approach to treatment is totally logical, well understood, and I think it is nothing less than HUGE. PTXX (Phase Therapeutics) was mentioned as a major company testing this modality of therapy, as well as Intralytix and Exponential Biotherpaies, both of which don't seem to be listed on American stock exchanges yet. As a biotech stock junky, having tired of missing various opportunities over the years by excessively careful watching (ENMD, AFFX, INCY, CEGE among some of the opportunities I have carefully tracked, and missed!!), I would say that this stock is going to really bounce up on Monday morning. Of course, it will trickle back down after the excitement is over. But a lot of investors read the NY TImes. Lets see if I'm right this time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next